TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01903408

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB
Description: The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB
Description: The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB
Description: The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB
Description: The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB
Description: The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
Study: NCT01790321

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LSF-filtering device
Description: LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 NTU turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSF-filtering device
Description: LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (\<0.5 NTU turbidity reduction), bacteria (\>Log 6 reduction), viruses (\>Log 4 reduction) and cysts (\>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, \>100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
Study: NCT02735837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Group
Description: Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo topical gel
Description: placebo topical gel was put into the periodontal pocket using an insulin syringe
Study: NCT02055573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready To Learn (RTL)
Description: See arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All Babies Cry (ABC)
Description: See arm description
Study: NCT04443387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
Study: NCT02191722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reading comics booklet
Study: NCT04570852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LiDCO
Description: We plan to elucidate the pathophysiology and molecular subtypes of acute pancreatitis in order to develop specific biomarkers and identify new drug targets. The evaluation will include an analysis of the impact of obesity and the metabolic profile during the disease course of acute pancreatitis.~Supportive treatments will be registered including an assessment of the fluid balance based on the fluid intake and loss and weight. Bioimpedance will be assessed at admission/day1, day 2, day 3,
Study: NCT01942044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus element, Xience prime, and Nobori

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promus element, Xience prime, and Nobori

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus element, Xience prime, and Nobori
Study: NCT01104246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testerone Transdermal System
Description: Transdermal testosterone applied daily for 4 weeks
Study: NCT03264781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclofem
Description: Intramuscularly injection 0.5 ml of Cyclofem or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclofem
Description: Intramuscularly injection 0.5 ml of Cyclofem or placebo
Study: NCT02128347

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Patient Portal
Description: RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
Study: NCT00247078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: widow spider antivenom
Description: 3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01917812

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Digital Activity Tracker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Activity Tracker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Activity Tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Text Messaging
Study: NCT03041701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Once every 2 weeks beginning on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Once every 2 weeks beginning on day 0.
Study: NCT00154804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin,Surgery, CCRT
Study: NCT00585013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
Study: NCT04443387

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A double-blinded, randomized, placebo-controlled study of VitD supplementation on 45 asthmatics with VitD deficiency was performed. Moderate to severe asthmatics between 18 and 65 years of age who had clinician-diagnosed asthma with 25-hydroxyvitamin D3 (25 D3) level less than 20ng/mL at the screening visit were recruited at the Rashid Hospital, Dubai, U.A.E., and the Zayed Military Hospital, Abu Dhabi, U.A.E. Subjects were excluded if they had used any previous VitD supplementation, had any other respiratory diseases or co-morbid conditions or were smokers. According to the American Academy of Family Physicians guidelines, participants received 50, 000 IU of VitD orally or placebo weekly over 8 weeks. Subjects were blinded to treatment and allocated to receive a VitD dose or placebo by the randomization schedule.
Study: NCT05448586

Intervention type: DRUG
Intervention: Opioid
Description: Use of balanced anesthesia including opioids during anesthesia for gynecologic cancer surgery
Study: NCT05817487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training (HIIT)
Description: Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The training sessions in the HIIT group involved five high-intensity intervals of 4 minutes each (running or walking on a treadmill) at 85% VO2max interspersed with 3 minutes of low-intensity walking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: crossover point(COP) exercise training
Description: Participants in both the COP and HIIT groups underwent 30 sessions of exercise performed over 10 weeks. The COP exercise training sessions involved 45 minutes of continuous exercise at the COP on a treadmill.
Study: NCT01506765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl-Cysteine (NAC)
Description: Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-Acetyl-Cysteine (NAC)
Description: Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
Study: NCT04103424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-term Exercise Training
Description: Participants will perform 2-weeks of supervised exercise training on a stationary bike.
Study: NCT00941538

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Experimental: Screening with EBV VCA/EBNA1-IgA testing
Description: Participants in the screening towns will be offered screening tests. Those with high-risk scores will be referred to a diagnostic workup examination using fiberoptic endoscopy examination and nasopharyngeal biopsies if suspicious lesions is observed.
Study: NCT01040286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: 2.0 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: 2.5mg
Study: NCT03767985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dichoptic video game therapy
Description: Dichoptic video gaming for 1 hour per week, viewed through the Oculus Rift.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occlusion therapy
Description: Occlusion therapy for 2 hours per day, 7 days a week
Study: NCT03367546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and Marrow Transplant
Description: Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
Study: NCT00688090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: MKC1106-MT
Description: Cancer Vaccine, Immunotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: MKCC1106-MT
Description: Cancer Vaccine, Immunotherapy
Study: NCT03160482

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
Study: NCT01378377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimasertib
Description: Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Study: NCT03041701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: Once every 2 weeks beginning on day 0.
Study: NCT02739490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Training Group
Description: Performs oriented exercise segmental stabilization lumbar-pelvic.
Study: NCT01378377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
Study: NCT03597009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (TVEC)
Description: Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort
Study: NCT00672386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ16269110
Description: 5 mg twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ16269110
Description: 10 mg twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ16269110
Description: 15 mg twice daily for 12 weeks
Study: NCT03160482

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry
Description: Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
Study: NCT02529397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Working Memory Training
Description: Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-adaptive cognitive training
Description: Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
Study: NCT00857441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting balloon
Description: Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liberté
Description: Bare metal stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liberté
Description: Bare metal stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA balloon catheter
Description: Percutaneous transluminal coronary angioplasty catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA balloon catheter
Description: Percutaneous transluminal coronary angioplasty catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus
Description: Paclitaxel eluting stent
Study: NCT03758118

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline
Description: Citicoline administered in oral solution
Study: NCT02496403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Medical Management (SMM)
Description: SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
Study: NCT04440644

Intervention type: BEHAVIORAL
Intervention: BBI
Description: administration of psychometric test

Intervention type: BEHAVIORAL
Intervention: BBI
Description: administration of psychometric test
Study: NCT03333174

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory monitoring
Description: The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory monitoring
Description: The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
Study: NCT04412252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tofacitinib-matching placebo administered as tablets or solution taken orally twice daily for 14 days
Study: NCT03263182

Intervention type: BEHAVIORAL
Intervention: Introduction of the Safe Childbirth Checklist
Description: 1. Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~2. Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~3. Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~4. Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training.
Study: NCT00672386

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 12 weeks
Study: NCT02888067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide 0.5 mg/kg
Description: Moderate neuromuscular blockade with rocuronium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide 1.0 mg/kg
Description: Deep neuromuscular blockade with rocuronium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex sodium 2 mg/kg
Description: Reversal with sugammadex sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex sodium 4 mg/kg
Description: Reversal with sugammadex sodium
Study: NCT03267290

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sonazoid- CEUS, CEMRI, CECT
Description: Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
Study: NCT02222519

Intervention type: DRUG
Intervention: Rocuronium
Description: Rocuronium 0.6mg/kg iv single dose

Intervention type: DRUG
Intervention: Rocuronium
Description: Rocuronium 0.6mg/kg iv single dose